Gilead Sciences to buy Pharmasset in $11 bln deal – Proactive Investors USA & Canada
 Globe and Mail |
Gilead Sciences to buy Pharmasset in $ 11 bln deal
Proactive Investors USA & Canada Drug maker Gilead Sciences (NASDAQ:GILD) has reached a definitive deal to acquire Pharmasset (NASDAQ:VRUS) for $ 11 billion, in a bid to step up the development of treatments for hepatitis C. Under the terms of the deal, Gilead will offer $ 137 per share … Pre-Market NASDAQ Movers (GEDU, VRUS, BSDM, LOOP, CLDX, NLST, GILD, MPEL, CEDC … GILD, VRUS, TRH, Y, TSN, TECD are Stocks to Watch on Nov-21 Morning Deutsche Bank (DB) Analysts Reiterate a "Buy" Rating on Gilead Sciences (GILD) |
